Ironwood Pharmaceuticals (IRWD) Rating Increased to Hold at BidaskClub

Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Wednesday.

Several other research firms have also issued reports on IRWD. HC Wainwright set a $13.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a “sell” rating in a research report on Monday, September 17th. Wells Fargo & Co reduced their price target on shares of Ironwood Pharmaceuticals to $18.50 and set an “outperform” rating on the stock in a research report on Thursday, November 1st. Mizuho reduced their price target on shares of Ironwood Pharmaceuticals to $15.00 and set a “buy” rating on the stock in a research report on Monday, November 19th. JPMorgan Chase & Co. reiterated an “underweight” rating and set a $11.00 price target (down previously from $20.00) on shares of Ironwood Pharmaceuticals in a research report on Wednesday, November 7th. Finally, Morgan Stanley set a $11.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a “sell” rating in a research report on Wednesday, November 7th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $16.50.

Ironwood Pharmaceuticals stock opened at $12.56 on Wednesday. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -13.51 and a beta of 1.50. Ironwood Pharmaceuticals has a twelve month low of $9.07 and a twelve month high of $21.20.



Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.24). The business had revenue of $68.69 million for the quarter, compared to analysts’ expectations of $93.48 million. During the same quarter in the prior year, the company posted ($0.18) earnings per share. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis. On average, equities research analysts anticipate that Ironwood Pharmaceuticals will post -1.01 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in IRWD. Point72 Asset Management L.P. raised its stake in shares of Ironwood Pharmaceuticals by 1,569.4% during the second quarter. Point72 Asset Management L.P. now owns 1,085,106 shares of the biotechnology company’s stock valued at $20,747,000 after acquiring an additional 1,020,106 shares during the last quarter. FMR LLC raised its stake in shares of Ironwood Pharmaceuticals by 3.1% during the second quarter. FMR LLC now owns 18,088,500 shares of the biotechnology company’s stock valued at $345,852,000 after acquiring an additional 547,724 shares during the last quarter. Vanguard Group Inc raised its stake in shares of Ironwood Pharmaceuticals by 3.2% during the third quarter. Vanguard Group Inc now owns 12,324,954 shares of the biotechnology company’s stock valued at $227,518,000 after acquiring an additional 377,177 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Ironwood Pharmaceuticals by 3.2% during the third quarter. Vanguard Group Inc. now owns 12,324,954 shares of the biotechnology company’s stock valued at $227,518,000 after acquiring an additional 377,177 shares during the last quarter. Finally, Fosun International Ltd bought a new position in shares of Ironwood Pharmaceuticals during the third quarter valued at $6,363,000. 93.32% of the stock is owned by hedge funds and other institutional investors.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Further Reading: How Important is Technical Analysis of Stocks

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply